The anticipated size of the immunostimulants market in 2022 was USD 108.22 billion and is estimated to be USD 113.54 billion in 2023.
Increase in the incidence of chronic diseases like asthma, allergic conditions, cancer, etc, and the availability of effective product pipelines of the companies involved in the research and development of immunomodulators accelerate the market growth. Future Market Insights has mentioned in its reports that the immunostimulants market will expand at a CAGR of 6.2% between 2023 and 2033, totaling around USD 206.96 billion by 2033.
Treatment and therapy of diseases become easy with increasing research and development spending on biological products and vaccines. Today, immunostimulants are actively used for the prevention of various diseases such as cancers, chronic disorders, autoimmune diseases like multiple sclerosis and rheumatoid arthritis, respiratory disorders, and others. This is possible due to rising government spending on research and development in biologics and biological products.
| Attributes | Details |
|---|---|
| Projected Forecast Value (2022) | USD 108.22 billion |
| Projected Forecast Value (2023) | USD 113.54 billion |
| Projected Forecast Value (2033) | USD 206.96 billion |
| Growth rate | 6.2% CAGR |
| Forecast period | 2023 to 2033 |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Global immunostimulants market grew at a CAGR of 5.0% between 2017 and 2022. Growth forecasts remain optimistic, with the market predicted to exhibit a CAGR of 6.2% between 2023 and 2033.
Historically, new vaccines were only available in low- and middle-income countries after they had been introduced in developed countries for several years. However, now vaccines are being rapidly introduced across emerging economies through the aid of global partners including the United Nations Children’s Fund (UNICEF) and the World Health Organization (WHO).
These global partners assist with vaccine prequalification and procurement while providing funding. Increasing access to vaccines in these under-penetrated markets will accelerate growth in the global immunostimulants market.
Over the past decade, public-private partnerships have been at the top of many agendas in international public health, and there has been an invariable incline in vaccine-focused public-private partnerships, specifically in developing countries.
Many nations' vaccination programs are supported by international organizations such as WHO, UNICEF, and the International Coordinating Group (ICG) on Vaccine Provision, as well as private non-profit groups such as the Global Alliance for Vaccines and Immunization (GAVI).
Immunostimulants have the potential to enhance the immune responses which are suppressed in cancer patients. Colony-stimulating factor (CSF) is a class of growth factors that minimize the risk of neutropenia and help cancer patients recover faster after chemotherapy.
Due to the wide range of applications of immunostimulants in the healthcare sector, sales of immunostimulants will increase at a considerable pace over the assessment period.
Expansion of the Biopharmaceutical Industry
Pharmaceutical manufacturers are launching products for the treatment of various chronic diseases. Because some diseases are still resistant to treatment, the concept of vaccination was developed. The most important indications are autoimmune diseases and oncology diseases. The biopharmaceutical industry is expanding, which will create opportunities for growth in the market.
Rise in Approvals of FDA
Increasing FDA approvals for biosimilars will propel the development of immunostimulants. This is primarily because biosimilars work the same as brand-name medicines at an affordable price and are easily available.
For example, in May 2022, the FDA approved the biologics license application for pegfilgrastim-pbbk, a biosimilar of Neulasta for the treatment of neutropenia caused by anticancer drugs.
Principal Consultant
Demand for Vaccines Mainly Depends on Disease Outbreaks
Demand for vaccines mainly depends on disease outbreaks, funding decisions, adoption by the National Immunisation Program (NIP), regulatory scenarios, and competing vaccine introduction priorities. Demand for such products remains highly uncertain amid funding sources and other favorable forces.
Besides this, manufacturers’ access to certain markets is restricted by varying pricing strategies, which further restricts the penetration of newly approved/launched vaccine products.
Development of Interferons is Costly
Development of interferons is costly in terms of research and development. Interferon development requires higher operating costs and necessitates a larger capital commitment. This is because biological medications are more complicated than small molecules and require more complicated manufacturing techniques.
High Cost of Colony-Stimulating Factors (CSF)
High cost of colony-stimulating factors (CSF) is limiting sales of immunostimulants. According to the Journal of Managed Care, chemotherapy costs have risen by 42% for breast cancer patients because of the administration of primary prophylactic (PP) G-CSF for the treatment of neutropenia which costs more than USD 250 per shot. Market for immunostimulants is projected to be hampered by the high cost of immunostimulation products.
Rising Demand for Immunostimulators in the USA Will Fuel Growth
The United States dominated the North American immunostimulants market, where the North American market is accounting for about 34.2%, and the trend is expected to continue over the forecast period. The United States is the most lucrative market for immunostimulants owing to the rise in cases of autoimmune diseases with a market share of 31.5%.
For instance, the National Institutes for Health (NIH) estimates that between 5%-8% of the United States, population is affected by autoimmune diseases, and the prevalence of this disorder is increasing dramatically. Along with this, increasing government spending on research in biologics is also driving the demand for immunostimulants in the country.
Increasing Awareness of Immunostimulants Therapy in Germany Will Boost Sales
Sales in Germany are set to increase at a CAGR of nearly 6.1% in the Europe immunostimulants market during the forecast period. Increasing focus to meet the unmet needs of patients and manufacturing capacities in the country is contributing to the demand for immunostimulants.
For instance, Merck, a company based in Germany, acquired Pandion Therapeutic, which is a biotechnology company developing novel therapeutics for autoimmune diseases.
Increasing manufacturing sites and drug development will promote growth in the immunostimulants market during the forecast period.
Growing Prevalence of Chronic Diseases in Japan Will Spur Demand for Immunostimulants
Demand for immunostimulants in Japan is projected to increase at a 3.4% CAGR over the assessment period.
Growth is associated with an increase in the unmet medical needs that necessitates the use of immunostimulants, and rapidly improving medical infrastructure in Japan.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Sales of Vaccines Will Continue Gaining Traction
Demand for vaccines will increase at a 6.4% CAGR over the assessment period, owing to their adoption for preventable diseases.
Vaccines are a simple and effective way to protect against diseases and they also lower the chance of contracting certain diseases. With an increasing number of diseases, there is a dramatic scientific breakthrough that resulted in advancements in vaccine production. The involvement of multiple manufacturers, as well as public and private sector investments in the discovery of modern vaccines will continue augmenting the growth in the market over the forecast period.
Demand for Immunostimulants for Cancer Treatment and Research Will Remain High
The oncology segment is expected to account for 32.2% of the total market share. Increasing prevalence of cancer and rising government funding, research grants, and fellowships for cancer research are anticipated to drive the market.
Primary benefit of immunostimulants in cancer patients is that it enhances the immune responses which are suppressed in cancer patients due to several functional factors, which will increase the adoption of immunostimulants over the forecast period.
Hospital Pharmacies Hold a Dominant Position in this Market
Hospital pharmacies are accounted for 44.1% of the total market share and the trend is expected to continue over the forecast period. High admission rates of patients for proper treatment within hospital settings across the globe will continue pushing sales in this segment over the forecast period.
Some of the key players are-
Some of the important developments are:
| Attribute | Details |
|---|---|
| Estimated Market Size (2023) | USD 113.54 billion |
| Projected Market Valuation (2033) | USD 206.96 billion |
| Value-based CAGR (2022 to 2032) | 6.2% |
| Forecast Period | 2017 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | USD Billion for Value |
| Key Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia & Pacific; East Asia; Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, China, Japan, South Korea, India, Bangladesh, Australia, New Zealand, GCC countries, South Africa, Israel |
| Key Market Segments Covered | Product, Application, End-User, Region |
| Key Companies Profiled | F. Hoffmann-La Roche Ltd; Merck KGaA; Bayer AG; Biogen Idec; GenSci; Sinovac; BioLegend; Invitrogen; OriGene; Biorbyt |
The market is valued at USD 113.54 billion in 2023.
The market is projected to expand at a CAGR of 6.2% through 2033.
The market is estimated to reach USD 206.96 billion by 2033.
Key players include F. Hoffmann-La Roche Ltd, Merck KGaA, Bayer AG, and more.
Rising demand due to chronic diseases, effective product pipelines.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Colony Stimulating Factors 5.2. Interferons 5.3. Interleukins 5.4. Vaccines 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application 6.1. Oncology 6.2. Respiratory 6.3. Chronic & Autoimmune Disorders 6.4. Others 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User 7.1. Hospital Pharmacies 7.2. Retail Pharmacies 7.3. Specialty Clinics 7.4. Online Pharmacies 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Western Europe 8.4. Eastern Europe 8.5. South Asia and Pacific 8.6. East Asia 8.7. Middle East and Africa 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. F. Hoffmann-La Roche Ltd 18.2. Merck KGaA 18.3. Bayer AG 18.4. Biogen Idec 18.5. GenSci 18.6. Sinovac 18.7. BioLegend 18.8. Invitrogen 18.9. OriGene 18.10. Biorbyt 19. Assumptions & Acronyms Used 20. Research Methodology
Chemicals & Materials
March 2023
REP-GB-12798
306 pages
Explore Healthcare Insights
View Reports
Immunostimulants Market
